Department of Ophthalmology and Visual Sciences, Yamagata University Faculty of Medicine, Yamagata, Japan.
Acta Ophthalmol. 2012 Nov;90(7):628-32. doi: 10.1111/j.1755-3768.2010.02066.x. Epub 2011 Jan 14.
To evaluate the efficacy of treatment of diffuse diabetic macular oedema (DME) with difluprednate ophthalmic emulsion 0.05% (Durezol™) in eyes before vitrectomy.
This study enrolled patients with diffuse DME for whom more than 3 months had passed since prior treatment. Nineteen eyes in 15 subjects were treated with difluprednate ophthalmic emulsion 0.05% four times daily for the first month and then twice daily for 2 months (treatment group). As a control group, 22 eyes in 11 subjects with DME were selected from subjects who underwent the steroid responder test.
In the treatment group, the mean visual acuity (VA) (±SD) was 0.38 ± 0.25 logMAR and mean retinal thickness was 461.1 ± 109.9 μm at baseline. After 1 month of treatment, the mean VA had improved to 0.29 ± 0.25 (Wilcoxon rank-sum test, p = 0.30), while mean retinal thickness had decreased to 372.1 ± 70.0 μm (p = 0.006). The rate of effective improvement in retinal thickness was 42% and that of VA was 26%. In the control group, changes in neither VA nor retinal thickness were significant.
Eye drop therapy using difluprednate ophthalmic emulsion 0.05% is a useful and effective treatment modality without surgical intervention or severe side-effects.
评估玻璃体切割术前使用双氯非那胺眼用乳液 0.05%（地塞米松）治疗弥漫性糖尿病性黄斑水肿（DME）的疗效。
本研究纳入了既往治疗后超过 3 个月的弥漫性 DME 患者。15 名患者的 19 只眼接受双氯非那胺眼用乳液 0.05% 每日 4 次治疗 1 个月，然后改为每日 2 次治疗 2 个月（治疗组）。作为对照组，从接受类固醇反应性测试的患者中选择了 11 名患者的 22 只眼患有 DME。
在治疗组中，平均视力（VA）（±SD）为 0.38±0.25 logMAR，视网膜厚度平均为 461.1±109.9μm。治疗 1 个月后，平均 VA 提高至 0.29±0.25（Wilcoxon 秩和检验，p=0.30），而视网膜厚度平均降低至 372.1±70.0μm（p=0.006）。视网膜厚度有效改善率为 42%，VA 改善率为 26%。对照组中，VA 和视网膜厚度均无明显变化。
使用双氯非那胺眼用乳液 0.05%滴眼治疗是一种有用且有效的治疗方法，无需手术干预或严重的副作用。
